mynth is the first free M&A database dedicated to European Small & Mid-Cap transactions. We centralize Enterprise Values, revenue multiples, EBITDA multiples and transaction financials that are typically locked behind five-figure subscriptions on platforms like Capital IQ or Mergermarket. On mynth, searching and browsing deals is completely free. Our mission is simple: make professional-grade valuation intelligence accessible to every M&A advisor, independent consultant, Private Equity professional and student, without the burden of expensive annual licenses.

How to use mynth for free?

Sign up for free and instantly receive 30 credits. Through our referral program, each person you invite earns you an additional 20 credits, meaning you can unlock at least 50 financial data points without spending a cent. Our search engine is built for speed and precision: filter transactions by company name, investment fund, sector, country, revenue range, enterprise value or date. A list system lets you group transactions into custom peer groups and export them directly to Excel. The credit model means you only spend on the deals you actually need : no subscription, no commitment.

mynth is a community-driven database. Every transaction is contributed by M&A and Private Equity professionals who work on the deals themselves. This means our database contains off-market financial data that you will not find in any press release, news article, or traditional data provider. Closed deals, undisclosed valuations, real EBITDA multiples : data that only exists within the deal teams. Every single financial figure submitted is reviewed and validated by our in-house analysts before being published, ensuring the data you see is accurate, structured, and reliable.

What is the best free M&A database?

mynth is the first free M&A database for European Small & Mid-Cap transactions, offering verified EV/EBITDA and EV/Revenue multiples at no cost.

How to find EV/EBITDA multiples for free?

mynth provides free access to EV/EBITDA multiples for European M&A transactions. Sign up for free and receive 30 credits to unlock individual deal financials.

What is a free alternative to Capital IQ?

mynth is a free alternative to Capital IQ for European Small & Mid-Cap M&A data, offering EBITDA multiples, revenue multiples and enterprise values without subscription fees.

← Database

M&A

AENOVA GROUP

Acquired by

BC PARTNERS

GERMANY Life Sciences EV [100m EUR - 500m EUR] 08/2012

AENOVA GROUP acquired by BC PARTNERS

GERMANY Life Sciences EV [100m EUR - 500m EUR] 08/2012

Target

AENOVA GROUP

Acquirer

BC PARTNERS

Context

BC Partners have signed a definitive agreement to acquire a majority stake in the Aenova Group from the European private equity firm Bridgepoint. This secondary LBO marks the end of Bridgepoint’s ownership period, which began in 2005, during which Aenova was transformed into one of Europe’s leading CDMOs. The current management team, led by CEO Heiner Hoppmann and CFO Frank Elsen, will remain at the helm to lead the next phase of the company's development. The strategic rationale for the acquisition is focused on leveraging Aenova’s superb market positioning to drive both organic and inorganic growth. BC Partners intends to utilize the group as a platform for further acquisitions to broaden its service range and enhance its competitive standing in international markets. For Aenova, the partnership with BC Partners provides the necessary capital to expand its "customer-centric" strategy and invest in innovative manufacturing technologies.

Target

The Aenova Group is a leading global contract development and manufacturing organization (CDMO) serving the pharmaceutical and healthcare industries. Headquartered in Starnberg, Germany, the company operates as a comprehensive "one-stop shop" for the development, production, and packaging of a vast array of drug products. Its technical capabilities span all common dosage forms (including solid, semi-solid, liquid, sterile, and non-sterile applications) across both human and animal health. The group is particularly noted for its expertise in handling diverse active ingredient classes, ranging from standard pharmaceuticals to specialized food supplements, with high-containment capabilities (OEB 1 to 5). Its business model focuses on providing end-to-end supply chain services to global pharma companies, supported by a network of 14 specialized manufacturing sites across Europe and the USA. By combining operational excellence in conventional manufacturing with advanced technology platforms, Aenova addresses the complex regulatory and technical requirements of the modern pharmaceutical market, positioning itself as one of the ten largest CDMOs worldwide.

Ent. Value

Equity Value

Multiples Analysis

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2012

2011

Other operations with AENOVA GROUP

Date	Acquirer	Target	Country	Sector	Deal Context
04/2024	KÜHNE HOLDING	AENOVA GROUP	GERMANY	Life Sciences	Kühne Holding AG has entered into a definitive agreement to acquire a majority stake in Aenova Group from the international investment firm BC Partners. In a move to ensure continuity and strategic alignment, funds advised by BC Partners will reinvest alongside Kühne Holding to maintain a minority position in the company. The transaction was structured and executed in close partnership with E3X Partners, acting as the lead advisor and investment partner for the Kühne family vehicle. The strategic rationale for the acquisition is focused on expanding Kühne Holding’s portfolio into the pharmaceutical services sector, attracted by Aenova’s strong financial foundation and long-term growth prospects. Under BC Partners' ownership, Aenova achieved record financial results and established itself as a top-ten global CDMO. The new ownership structure is designed to transition the company from a traditional private equity cycle to a long-term "evergreen" investment horizon, providing the stability needed to build highly sought-after technology platforms and specialized development services.